Researchers are putting a long-known acetylcholinesterase inhibitor lineage back into the spotlight with buntanetap, a modern derivative of physostigmine, now in Alzheimer’s disease clinical trials. The work traces the compound’s pharmacology from early poison investigations to controlled medicinal dosing intended to preserve acetylcholine signaling in neurodegenerative disease. The news centers on the program’s positioning as a potential cognition-focused therapy, leveraging the same enzyme mechanism associated with longer-lasting acetylcholine at synapses. The historical pharmacology is a direct match to the Alzheimer’s rationale: progressive neuronal loss threatens cholinergic signaling that supports attention, learning, and memory. While details of the clinical readouts weren’t provided in the article, the framing highlights a development push toward “nearer-the-finish-line” translation for buntanetap in the clinic.